Saturday, October 31, 2026

“FLESH AGAINST AXES” The Sickening Cruelty of Pyongyangs Human Shield Show

North Korea showcased elite martial arts and military techniques in a demonstration for Kim Jong Un, emphasizing loyalty and strength.

ENEMY FIRST: While North Korea Aims ICBMs, South Korean Officials Are Busy Sending Them ‘Vitamin C Diplomacy’

Jeju Island plans to revive its Vitamin C diplomacy by sending tangerines to North Korea, aiming to enhance inter-Korean relations.

Jennie Stuns with Risqué Stage Outfits, Dividing Social Media

BLACKPINK's Jennie wowed fans with daring outfits at her LA concert, sparking mixed reactions over her provocative fashion choices.

News1

Author's Latest

Revolutionary Battery Technology: How g-C₃N₄ Enhances Lithium-Ion Movement for High-Energy Density EVs

A new battery electrode technology significantly improves lithium-ion movement and output degradation caused by thicker electrodes.

Coway vs. Traditional Mobility Aids: Why the New Wearable Robot is a Game Changer for Seniors

Coway unveils a wearable robot to assist seniors with walking, starting pre-orders ahead of the official launch in October.

NeogenLogic Receives U.S. Patent Decision for AI Technology to Identify Cancer Vaccine Targets

SCL Science subsidiary NeogenLogic has received a decision to grant a U.S. patent for technology that uses artificial intelligence to identify cancer targets most likely to trigger an immune response in individual patients.

HLB Cholangiocarcinoma Drug FDA Decision Due in 3 Days: No Additional Review Issues Reported

HLB’s bile duct cancer drug lirafugratinib is three days away from its FDA decision, with no additional review or manufacturing-site issues reported so far, keeping attention focused on the U.S. approval outcome.

Lecanemab Shows Manageable Safety Profile in Korean Patients

A real-world analysis of Korean patients treated with lecanemab found that most infusion-related reactions and amyloid-related imaging abnormalities (ARIA) were mild or asymptomatic, while baseline MRI assessment and regular monitoring remained important.

Daewoong Pharma Unveils First Patient Data From Phase 2 Trial of Pulmonary Fibrosis Drug Bersiporocin

Daewoong Pharmaceutical has presented baseline characteristics for all 104 patients enrolled in the global Phase 2 trial of bersiporocin, its investigational treatment for idiopathic pulmonary fibrosis

Matica Bio Partners With Bondwell Technologies to Develop Next-Generation Protein Manufacturing Processes

Matica Bio, the U.S. subsidiary of CHA Biotech, will provide process optimization services to Bondwell Technologies to support production and commercialization of next-generation protein biomaterials.

From Research Breakthroughs to New Drugs: Helping K-Drug Candidates Reach Global Markets

South Korea is strengthening support across the commercialization process to help domestically discovered drug candidates move beyond licensing deals and become globally developed medicines.

I Started a Company to Solve Patient Problems. For This Doctor-Founder, It Took Seven Years to Break Through

AITRICS CEO Kim Kwang-jun spent seven to eight years turning a clinical need he identified as a geriatrician into an AI medical product that could actually be used in hospitals.

ST Pharm Secures Record $66.1 Million Oligonucleotide API Supply Contract

ST Pharm has won a $66.1 million oligonucleotide drug substance supply contract from a global U.S.-based biotech company, marking its largest single oligonucleotide contract to date.

Unlocking the Future: How IVL3004’s Monthly Injection Revolutionizes Addiction Treatment

Inventage Lab receives U.S. patent approval for a monthly drug addiction treatment, aiming for clinical trials and global commercialization.

HLB’s LYRFIGTU: What Does FDA’s Conditional Acceptance Mean for Biliary Cancer Treatment?

HLB's new bile duct cancer drug candidate, Liraglutide, is expected to be named LYRFIGTU in the U.S., with FDA approval on September 25.

GCC2005: Breakthrough CAR-NK Therapy Shows 62.5% Response Rate in Clinical Trial

GC Cell announced interim results of its clinical trial for GCC2005 (CD5 CAR-NK) presented at ICBMT 2026 on September 17.

2026 Citizen Human Rights Award: Honoring Activism and Legal Excellence in South Korea

Human rights advocate Sek Al Mamoon and the Korean Women's Labor Association recognized for their work on migrant workers and refugee issues.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.